A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 2091-2098

  Smythe, Wynand ^a   Khandelwal, Akash ^b   Merle, Corinne ^c   Rustomjee, Roxana ^d   Gninafon, Martin ^e   Lo, Mame Bocar ^f   Sow, Oumou Bah ^g   Olliaro, Piero L ^h   Lienhardt, Christian ⁱ   Horton, John ^j   Smith, Peter ^a   McIlleron, Helen ^a   Simonsson, Ulrika S H ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UPPSALA UNIVERSITY   (Sweden)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^e Programme National de Lutte Contre la Tuberculose   (Benin)

^f Programme National de Lutte contre la Tuberculose   (Senegal)

^g CHU Ignace Deen   (Guinea)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

ⁱ INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^j Tropical Projects   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL MODEL; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SEMIMECHANISTIC PHARMACOKINETIC ENZYME TURNOVER MODEL; SHORT COURSE THERAPY; STEADY STATE; TURNOVER TIME;

ADOLESCENT; ADULT; AGED; AGING; ALGORITHMS; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HIV INFECTIONS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MODELS, STATISTICAL; RIFAMPIN; SEX CHARACTERISTICS; SOFTWARE; STOCHASTIC PROCESSES; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84863393649     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05792-11     Document Type: Article

References (43)

1. Acocella G. 1978. Clinical pharmacokinetics of rifampicin. Clin. Pharmacokinet. 3:108-127.
2. Acocella G. 1983. Pharmacokinetics and metabolism of rifampin in humans. Rev. Infect. Dis. 5(Suppl. 3):S428-S432.
3. Anderson BJ, Holford NH. 2008. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48:303-332. (Pubitemid 351738156)
4. Anderson BJ, Holford NH. 2009. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab. Pharmacokinet. 24:25-36.
5. Beal S, Sheiner LB, Boeckmann A, Bauer RJ. 2009. NONMEM user's guides 1989-2009. Icon Development Solutions, Ellicott City, MD.
6. Benedetti SM, Dostert P. 1994. Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environ. Health Perspect. 102:101-105.
7. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. 2011. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13:134-151.
8. Blumberg HM, et al. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
9. Chen J, Raymond K. 2006. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann. Clin. Microbiol. Antimicrob. 5:3. doi:10.1186/1476-0711-5-3.
10. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
11. Diacon AH, et al. 2007. The early bactericidal activity of high-dose rifampin in patients with sputum smear-positive pulmonary tuberculosis. Antimicrob. Agents Chemother. 51:2994-2996. (Pubitemid 47206244)
12. Faber KN, Muller M, Jansen PLM. 2003. Drug transport proteins in the liver. Adv. Drug Deliv. Rev. 55:107-124. (Pubitemid 36082884)
13. Geick A, Eichelbaum M, Burk O. 2001. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276:14581-14587.
14. Gumbo T, et al. 2007. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 51:3781-3788. (Pubitemid 350057771)
15. Harling K, Ueckert S, Hooker AC, Jonsson EN, Karlsson MO. 2010. Abstr. 19th Popul. Approach Group Eur. Meet., abstr 1842. www.page-meeting.org/?abstr= 1842.
16. Hassan M, et al. 1999. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. Br. J. Clin. Pharmacol. 48:669-677. (Pubitemid 29520590)
17. Holford NHG. 1996. A size standard for pharmacokinetics. Clin. Pharmacokinet. 30:329-332. (Pubitemid 26177179)
18. Holford NHG. 2005. Abstr. 14th Popul. Approach Group Eur. Meet., abstr 738. www.page-meeting.org/?abstr=738.
19. Holford NHG, Karlsson MO. 2008. Abstr. 17th Popul. Approach Group Eur. Meet., abstr 1434. www.page-meeting.org/?abstr=1434.
20. Jamis-Dow, CA, Katki AG, Collins JM, Klecker RW. 1997. Rifampin and rifabutin and their metabolism by human liver esterases. Xenobiotica 27: 1015-1024. (Pubitemid 27450594)
21. Jonsson EN, Karlsson MO. 1998. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64. (Pubitemid 29049052)
22. Karlsson MO, Sheiner LB. 1993. The importance of modelling interoccasion variability in population pharmacokinetic analyses. J. Pharmacokinet. Biopharm. 21:735-750. (Pubitemid 24052760)
23. Khandelwal A, Harling K, Jonsson EN, Hooker AC, Karlsson MO. 2011. A fast method for testing covariates in population PK/PD models. AAPS J. 13:464-472.
24. Lin JH. 2003. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv. Drug Deliv. Rev. 55:53-81. (Pubitemid 36082882)
25. Lindbom L, Ribbing J, Jonsson EN. 2004. Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Comput. Methods Programs Biomed. 75:85-94. (Pubitemid 38798039)
26. Lindbom L, Pihlgren P, Jonsson EN. 2005. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput. Methods Programs Biomed. 79:241-257. (Pubitemid 41196689)
27. Loos U, et al. 1985. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin. Wochenschr. 63:1205-1211. (Pubitemid 16169743)
28. Loos U, Musch E, Jensen JC, Schwabe HK, Eichelbaum M. 1987. Influence of the enzyme induction by rifampicin on its presystemic metabolism. Pharmacol. Ther. 33:201-204. (Pubitemid 17113110)
29. McIlleron H, et al. 2007. Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers. J. Antimicrob. Chemother. 60:1398-1401.
30. Mitchison DA. 2000. Role of individual drugs in the chemotherapy of tuberculosis. Int. J. Tuberc. Lung Dis. 4:796-806.
31. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. 2003. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 42:819-850. (Pubitemid 36995083)
32. Peloquin CA. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169-2183. (Pubitemid 35252827)
33. Peloquin C. 2003. What is the 'right' dose of rifampin? Int. J. Tuberc. Lung Dis. 7:3-5. (Pubitemid 36427025)
34. R. 2011. R: a language and environment for statistical computing. Institute for Statistics and Mathematics, WU Wien, Vienna, Austria. http://www.R-project.org/.
35. Ruslami R, et al. 2006. Evaluation of high-versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis. Antimicrob. Agents Chemother. 50:822-823. (Pubitemid 43191013)
36. Sahai J, et al. 1997. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann. Intern. Med. 127:289-293. (Pubitemid 27352050)
37. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. 2007. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 34:711-726. (Pubitemid 47477040)
38. Staudinger JL, Chenshu X, Cui YJ, Klaasen CD. 2010. Nuclear receptormediated regulation of carboxylesterase expression and activity. Expert Opin. Drug Metab. Toxicol. 6:261-271.
39. van Ingen J, et al. 2011. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin. Infect. Dis. 52:e194-e199.
40. West GB, Brown JH, Enquist BJ. 1997. A general model for the origin of allometric scaling laws in biology. Science 276:122-126. (Pubitemid 27161259)
41. West GB, Brown JH, Enquist BJ. 1999. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 284:1677-1679. (Pubitemid 29291379)
42. Wilkins JJ, et al. 2008. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob. Agents Chemother. 52:2138-2148. (Pubitemid 351758551)
43. World Health Organization. 2009. WHO/HTM/TB/2009.420 2009. Treatment of tuberculosis: guidelines for national programmes. Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland.